DNAiTECH

What DNAiTECH does

DNAiTECH is a New Zealand-based biotechnology company founded in 2020 by Murray Broom, developing portable, battery-powered point-of-care (POC) molecular diagnostic systems for remote and resource-limited settings. The company's core technology combines Loop-mediated Isothermal Amplification (LAMP) with CRISPR-based detection, integrated into paper-based microfluidic cartridges (PLACID platform), and supported by proprietary sample preparation instruments: the Denaturator (battery-powered boiling unit that heats samples to 90-100°C in 90 seconds) and S-TECH (syringe-driven nucleic acid extraction system using track-etched polycarbonate membranes that eliminates cold-chain requirements). The product portfolio spans the Gen 3.1 diagnostic instrument with validated assays for MRSA/MSSA, Yellow Fever, and Measles, plus the Gen 3.2 system scheduled for September 2026 release featuring 8-well multiplexed pathogen screening.

The company targets four primary customer segments: remote healthcare clinics lacking centralized laboratory access, the apiculture industry (bee pathogen detection), agriculturalists and viticulture operators (field diagnostics, grape cultivar verification), and veterinary services. Revenue mechanics combine hardware sales (diagnostic instruments, S-TECH devices available for worldwide shipping), assay and consumable sales (pathogen-specific test chips and reagents), and subcontracted R&D partnerships (notably Institut Pasteur Dakar for Yellow Fever and Measles diagnostics, with field trials conducted in Senegal in September 2025). Go-to-market is direct enterprise sales targeting remote clinics, agriculturalists, veterinarians, and field researchers, with pricing disclosed only via direct contact rather than public channels.

DNAiTECH operates from the Marlborough Research Centre in Blenheim, New Zealand, with a small team (1-10 employees) supported by a science advisory board including Rutherford Medal recipient Dr. Warren Tate and Professor Wayne Patrick. The company has raised approximately NZ$1.7M across a pre-Seed round led by Sprout Agritech (October 2024, NZ$1M) and multiple New Zealand government grants including Callaghan Innovation and Ministry for Primary Industries. Operating geographies span Oceania (domestic), Africa (Senegal), and Europe (Spain), with S-TECH products available for global shipping.

Name

DNAiTECH

Legal name

DNAiTECH Ltd.

Website

https://dnaitech.com

Company type

Private

Founded year

2020

Operating status

Operating

Headcount range

1–10 employees

Short description

DNAiTECH develops portable, battery-powered LAMP-CRISPR point-of-care diagnostic systems combining paper-based microfluidics with proprietary sample preparation instruments, serving remote healthcare clinics, beekeepers, agriculturalists, veterinarians, and field researchers globally.

Ownership category

akta.pro rank

Product category

Molecular Diagnostics

NAICS

Analytical Laboratory Instrument Manufacturing (334516), Medical and Diagnostic Laboratories (62151)

SIC

Laboratory Analytical Instruments (3826), In Vitro & In Vivo Diagnostic Substances (2835)

akta.pro primary industry

Molecular POCT / NAAT Systems (PCR/Isothermal platforms & cartridges) (HLAHAOAI)

akta.pro secondary industries

Molecular Diagnostics (PCR/NAAT/NGS-based IVD) (HLAHAAAD), Molecular Biology & Genomics Instruments (PCR/qPCR, Sequencing, Microarrays) (HLAGAIAF), Multiplex & High-Throughput Diagnostics Platforms (microarrays, digital PCR, lab automation-enabled assays) (HLAAALAL), Rapid On-Site Environmental Testing Kits & Instruments (Lateral Flow, PCR, ATP Devices) (AFALAEAK)

Keywords

• Point-of-care diagnostics
• Molecular diagnostics
• LAMP-CRISPR technology
• Nucleic acid extraction
• Battery-powered instruments

Headquarters

HQ city

Grovetown

HQ country

New Zealand

HQ region

Oceania

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Technology or R&D, Supply Chain, Marketing or Sales, Operations

Revenue model

1. Diagnostic Instruments and Hardware: Sale of specialized portable diagnostic instruments including Denaturator, S-TECH extraction devices, and Gen series diagnostic systems (Gen 3.1, upcoming Gen 3.2). Hardware forms the core product platform.
2. Diagnostic Tests and Consumables: Sale of diagnostic test chips and reagents including MRSA/MSSA detection tests, Yellow Fever tests, Measles tests, and application-specific assays for agriculture (grape cultivar typing, bee pathogen detection).
3. S-TECH Sample Processing Products: S-TECH devices and track-etched membranes for nucleic acid extraction, subcellular particle isolation, and sample preparation. Sold for biomedical, agritech, veterinary, and environmental applications.

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

Core offering

DNAiTECH develops and manufactures portable point-of-care molecular diagnostic instruments (Denaturator, Gen 3.1, Gen 3.2) and proprietary consumable assays built on its PLACID paper-based LAMP-CRISPR platform. The integrated system combines the S-TECH extraction module with isothermal amplification and CRISPR-based detection in a battery-powered format that delivers sample-to-answer molecular testing without thermocyclers, cold-chain logistics, or centralized laboratory infrastructure. Target applications span clinical infectious disease (MRSA/MSSA, Yellow Fever, Measles), apiculture pathogen screening, viticulture cultivar typing, and veterinary diagnostics.

Product overview

DNAiTECH is a New Zealand point-of-care molecular diagnostics company developing portable, battery-powered diagnostic systems. The product portfolio centers on the PLACID system (paper-based LAMP-CRISPR Integrated Diagnostics) combined with S-TECH sample processing technology and the Denaturator for sample preparation. The Gen 3.1 and Gen 3.2 instrument generations provide the hardware platform, while specific assay products target applications in human health (MRSA/MSSA, measles, yellow fever), animal health (bee pathogens), and agritech (grape cultivar typing). The technology stack combines LAMP isothermal amplification for robustness with CRISPR-based detection for high specificity, delivering results visible to the naked eye or smartphone camera in minutes rather than days.

Differentiator

Problem solved

Functional benefit

Brands

• PLACID: Paper-based LAMP-CRISPR Integrated diagnostics - a point-of-care molecular testing approach that brings disease detection out of laboratories to primary care settings.
• S-TECH
• Denaturator
• Gen 3.1
• Gen 3.2

Products and services

• PLACID (Paper-based LAMP-CRISPR Integrated Diagnostics) Proprietary paper-based microfluidic diagnostic platform that combines LAMP isothermal amplification with CRISPR-based detection. Designed as the foundational technology stack underpinning DNAiTECH's consumable assays and instruments for clinical, veterinary, apiculture, and agricultural applications.
• S-TECH Sample Preparation System Integrated sample preparation module using track-etched polycarbonate membranes to extract nucleic acids from raw biological samples. Designed as the front end of the sample-to-answer workflow that feeds into DNAiTECH's LAMP-CRISPR detection instruments.
• Denaturator Sample processing device that prepares biological samples prior to loading into DNAiTECH's Gen 3.x diagnostic instruments, completing the front-end of the sample-to-answer workflow.
• Gen 3.1 Diagnostic System Current-generation benchtop diagnostic instrument that runs DNAiTECH's consumable assays, including MRSA/MSSA Staphylococcus aureus detection, with battery-powered operation enabling point-of-care molecular testing.
• Gen 3.2 Diagnostic System Upcoming next-generation benchtop diagnostic instrument positioned to expand DNAiTECH's assay menu and throughput beyond the Gen 3.1 platform.
• Staphylococcus aureus (MRSA/MSSA) Assay Consumable molecular assay for detecting Methicillin-Resistant Staphylococcus aureus (MRSA) and Methicillin-Sensitive Staphylococcus aureus (MSSA), run on the Gen 3.1 diagnostic instrument for clinical and point-of-care use.
• Yellow Fever Virus Assay Consumable molecular assay for detecting Yellow Fever virus on the Gen 3.1 diagnostic instrument, designed for clinical and point-of-care deployment.
• Measles Virus Assay Consumable molecular assay for detecting Measles virus on the Gen 3.1 diagnostic instrument, designed for clinical and point-of-care deployment.
• Bee Pathogen Detection Assays Suite of consumable molecular assays for field-level screening of apiculture pathogens including American Foulbrood, European Foulbrood, Deformed Wing Virus A, Deformed Wing Virus B, Nosema ceranae, and Nosema apis, supported by collaborations with Massey University Bee Lab and the University of Adelaide ARC Training Centre for Bee Health.
• Grape Cultivar Typing Portable molecular genotyping service for grapevine cultivar identification, supported by DNAiTECH's partnership with Plant & Food Research, used by viticulture industry players to verify cultivar identity and prevent mis-propagation.

Quantifiable outcome

• Reduces diagnostic turnaround time from days to minutes
• +3 more outcomes

Named customers1 record

Segments5 records

Ideal customer profiles4 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability2 records

Feature5 records

Partnerships

Four partnerships are on record, tiered core and minor.

• Institut Pasteur, DakarcoreStrategic or Co-development PartnerDNAiTECH subcontracted by Institut Pasteur Dakar to develop rapid proof-of-concept diagnostic tests for Yellow Fever virus and Measles virus. Trials conducted in Senegal September 2025.
• Apiculture New ZealandminorStrategic or Co-development PartnerIndustry association for New Zealand beekeeping. Collaboration on American Foulbrood and varroa mite detection program for the apiculture industry.
• Dr. Javier Quinteiro and Wine Researchers (Spain)minorStrategic or Co-development PartnerAcademic collaboration for grape cultivar typing using LAMP technology. DNAiTECH Gen 2 instrument used to verify Albariño cultivars in Spain.
• Marlborough Research CentreminorOthersLocation of DNAiTECH headquarters. Research facility providing infrastructure and ecosystem for agricultural and scientific research in Marlborough, New Zealand.

Scale indicators3 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• LexaGene: LexaGene developed the MiQLab system for rapid, automated PCR-based pathogen detection in veterinary, food safety, and human clinical applications. Its multi-vertical POC molecular positioning (especially veterinary and agricultural overlap) is closely comparable to DNAiTECH's.
• Cepheid (Danaher): Cepheid's GeneXpert is the dominant cartridge-based POC NAAT platform, widely deployed in clinics and global-health settings. It is the most direct competitive analogue to DNAiTECH's vision of rapid, decentralized molecular diagnostics for pathogens like MRSA and tropical diseases.
• Cue Health: Cue Health developed a consumer/professional portable molecular diagnostic platform with connected cartridge-based testing. It is closely comparable to DNAiTECH in form-factor ambition and decentralization use cases, although focused on respiratory and at-home testing.
• Mesa Biotech (now part of Revvity / previously BioMérieux-acquired Accula): Mesa Biotech developed the Accula portable PCR system for rapid POC molecular testing (e.g., influenza, RSV, SARS-CoV-2). It is a direct peer in portable cartridge-based NAAT, with comparable application focus on decentralized clinical diagnostics.
• Atomo Diagnostics: Atomo Diagnostics (Australia/NZ region) develops integrated rapid diagnostic test devices for infectious disease and chronic conditions. It is a regionally proximate peer with similar POC ambitions and a comparable pre-commercial/early-commercial stage profile.
• QuantuMDx: QuantuMDx is building a portable, battery-powered qPCR device (Q-POC) targeted at decentralized clinical and global-health use cases. Its technology and target customer set closely mirror DNAiTECH's POC NAAT positioning.
• Sense Biodetection: Sense Biodetection is developing instrument-free, single-use molecular diagnostic tests based on isothermal amplification — directly comparable to DNAiTECH's LAMP-CRISPR paper-microfluidic ASSURED-style approach.
• OptiGene: OptiGene develops isothermal amplification instruments and reagents (Genie series) for field and POC molecular biology. It is directly comparable as a specialist isothermal-amplification platform, although more research/field-oriented than clinical.

Broad incumbents

• Abbott: Abbott's m-PIMA and broader rapid diagnostics portfolio (including Binax and ID NOW) targets the same decentralized molecular-testing market as DNAiTECH. As a large diversified diagnostics incumbent, Abbott offers overlapping capabilities through a much broader product portfolio.
• BioMérieux (BioFire): BioFire FilmArray is a leading multiplexed syndromic POC molecular panel, used in clinical and global-health applications. It overlaps with DNAiTECH's multiplex pathogen detection capability but as part of a much larger diagnostic franchise.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/dnaitech-ltd

Revenue estimate

Valuation estimate

Number of profiles

Profiles11 records

Funding overview

Funding rounds4 records

Investors5 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DNAiTECH